Warnings about potential hepatotoxicity risks associated with use of diclofenac have been added to the labels of all products containing the nonsteroidal anti-inflammatory drug, the Food and Drug Administration said. A notice posted on the FDA's MedWatch site said that the manufacturers—Endo Pharmaceuticals Inc. and Novartis Consumer Health Inc.—had revised the “hepatic effects” section of the diclofenac topical gel label to include new warnings and precautions about the potential for elevated liver function tests (LFTs) during treatment with diclofenac products, including the topical gel formulation marketed as Voltaren Gel 1%. There have been postmarketing reports of severe hepatic reactions, including...